肿瘤治疗电场治疗铂耐药卵巢癌:ENGOT-ov50/GOG-3029/INNOVATE-3关键性3期随机研究结果
ENGOT-ov50/GOG-3029/INNOVATE-3关键性3期随机研究评估肿瘤治疗电场(TTFields)联合紫杉醇(PTX)对比PTX在铂耐药卵巢癌(PROC)患者中的疗效与安全性。共558例患者随机1:1接受TTFields(200 kHz;≥18小时/天)+PTX(80 mg/m²每周)或PTX。ITT人群 median OS 12.2个月 vs 11.9个月(HR 1.01;95%CI 0.83-1.24;p=0.89),未显著改善OS;探索性事后分析中PLD初治患者 median OS 16个月 vs 11.7个月(nominal HR 0.67;95%CI 0.49-0.94;p=0.03)。
要点
- ITT人群TTFields+PTX对比PTX的OS无显著差异(HR 1.01;95%CI 0.83-1.24;p=0.89)。
- 探索性事后分析显示PLD初治患者TTFields+PTX可能获益(nominal HR 0.67;95%CI 0.49-0.94;p=0.03)。
- TTFields相关皮肤不良事件多为1/2级,发生率83.6%,无新安全信号。
核心结论
- ITT人群中TTFields+PTX对比PTX未显著改善OS。
- 探索性事后分析提示PLD初治患者中TTFields治疗可能具有有利的获益-风险特征。
- 未发现新的安全信号。
研究设计与样本
- 关键性3期随机研究ENGOT-ov50/GOG-3029/INNOVATE-3。
- 纳入铂耐药卵巢癌成人患者,既往总治疗线数≤5线,其中铂耐药疾病既往治疗≤2线,ECOG PS 0-1。
- 2019年3月至2021年11月共558例患者随机1:1接受TTFields(200 kHz;≥18小时/天)+PTX(80 mg/m²每周)或PTX。
- TTFields+PTX组280例,PTX组278例;ECOG PS 0者占60.2%;中位年龄62岁(范围22-91岁);24.4%既往接受4线及以上治疗。
- 主要终点为总生存期(OS)。
主要发现
- ITT人群 median OS:TTFields+PTX组12.2个月 vs PTX组11.9个月(HR 1.01;95%CI 0.83-1.24;p=0.89)。
- 两组≥3级不良事件(AEs)相似。
- TTFields治疗组83.6%患者发生1/2级器械相关皮肤不良事件。
- 探索性事后分析中PLD初治患者 median OS:TTFields+PTX组(n=113)16个月 vs PTX组(n=88)11.7个月(nominal HR 0.67;95%CI 0.49-0.94;p=0.03)。
关键数值与推荐
- TTFields+PTX组与PTX组ITT人群OS的HR为1.01(95%CI 0.83-1.24;p=0.89)。
- PLD初治患者探索性事后分析中TTFields+PTX组(n=113)对比PTX组(n=88)的nominal HR为0.67(95%CI 0.49-0.94;p=0.03)。
- TTFields治疗组1/2级器械相关皮肤不良事件发生率为83.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- PLD初治患者的分析为探索性事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tumor Treating Fields (TTFields) are electric fields that disrupt processes critical for cancer cell viability and tumor progression. The pivotal, phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 study evaluated efficacy and safety of TTFields therapy with paclitaxel (PTX) vs PTX in patients with platinum-resistant ovarian cancer (PROC). PATIENTS AND METHODS: Adult patients with PROC with ≤ 5 total prior lines of therapy (LOT), including ≤ 2 prior LOT for platinum-resistant disease, and ECOG PS of 0-1 were randomized 1:1 to receive TTFields (200 kHz; ≥ 18 h/day) + PTX (80 mg/m2 weekly) or PTX. Primary endpoint was overall survival (OS). Exploratory post-hoc analyses assessed OS in pegylated liposomal doxorubicin (PLD)-naive patients. RESULTS: Between March 2019 and November 2021, 558 patients (ECOG PS 0, 60.2 %; median [range] age, 62 [22-91] years) were assigned TTFields+PTX (n = 280) or PTX (n = 278). 24.4 % had 4 + prior LOT. Median OS was 12.2 months with TTFields+PTX vs 11.9 months with PTX (HR, 1.01; 95 % CI, 0.83-1.24; p = 0.89). Grade ≥ 3 adverse events (AEs) were similar between treatment groups. Grade 1/2 device-related skin AEs occurred in 83.6 % of patients receiving TTFields therapy. In exploratory post-hoc analysis in PLD-naive patients, median OS was 16 months with TTFields+PTX (n = 113) vs 11.7 months with PTX (n = 88; nominal HR, 0.67; 95 % CI, 0.49-0.94; p = 0.03). CONCLUSIONS: No new safety signals were identified. TTFields+PTX did not significantly improve OS compared with PTX in the intent-to-treat population. An exploratory post-hoc analysis suggests a potentially favorable benefit-risk profile for TTFields therapy in PLD-naive patients.
引用
- Vergote I, Copeland LJ, Van Gorp T, et al. Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study. Eur J Cancer. 2025. PMID: 40010134. doi:10.1016/j.ejca.2025.115306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。